{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "openFDA", "hasEmail": "mailto:open@fda.hhs.gov"}, "description": "The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.", "distribution": [{"@type": "dcat:Distribution", "downloadURL": "http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm", "mediaType": "application/pdf"}], "identifier": "6c697267-fe17-4c66-8c6d-da38ab9b723b", "issued": "2021-02-25", "keyword": ["cder", "rems"], "landingPage": "http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm", "license": "http://opendefinition.org/licenses/odc-odbl/", "modified": "2013-11-12", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Approved Risk Evaluation and Mitigation Strategies"}